SELLAS Life Sciences Group, Inc. (SLS) compared with its closest peers (RIGL, SNDX, PGEN, AGIO, BEAM). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Rigel Pharmaceuticals, Syndax Pharmaceuticals and Prelude Therapeutics: named a competitor in the 10-K.
| Company | Market Cap | P/E |
|---|---|---|
| Rigel Pharmaceuticals, Inc. (RIGL) | $882.25M | 2.7 |
| Syndax Pharmaceuticals, Inc. (SNDX) | $1.61B | — |
| Precigen, Inc. (PGEN) | $2.45B | — |
| Agios Pharmaceuticals, Inc. (AGIO) | $2.00B | — |
| Beam Therapeutics Inc. (BEAM) | $2.48B | — |
| Prelude Therapeutics Incorporated (PRLD) | $366.30M | — |
| Nuvation Bio Inc. (NUVB) | $2.13B | — |
| Celldex Therapeutics, Inc. (CLDX) | $2.90B | — |
| Zenas BioPharma, Inc. (ZBIO) | $1.97B | — |
| MeiraGTx Holdings plc (MGTX) | $1.23B | 15.6 |
| Sector P/E (Healthcare) | 19.4 |
| Industry P/E (Pharmaceutical Products) | 15.1 |
SLS overview · SLS earnings · SLS financials · SLS KPIs · SLS documents · SLS ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.